NXG.V NexgenRX Inc.
- Market cap
- CAD 46.9M
- P/E
- 22.0x
- P/B
- 6.07x
- ROE
- 47.3%
- Dividend yield
- 2.76%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NXG.V undervalued?
Graham numberNXG.V trades 143.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NexgenRX Inc. fundamental analysis
No fundamental analysis for NexgenRX Inc. yet.
NexgenRX Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NexgenRX Inc.
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. The company offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. It also provides proprietary computer software, and ancillary services. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada.
Full company profileNexgenRX Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NexgenRX Inc. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.75M | 5.67M | 7.17M | 9.54M | 11.0M | 11.8M | 12.8M | 13.8M | 16.5M | 17.9M | 20.3M |
| Gross Profit | 4.64M | 4.55M | 6.04M | 8.37M | 9.67M | 9.81M | 10.2M | 10.8M | 13.1M | 14.9M | 17.3M |
| Operating Income | 517K | -530K | -558K | 93.5K | 2.16M | 2.20M | 288K | -144K | 1.20M | 2.23M | 4.55M |
| EBITDA | - | -472K | -321K | 816K | 2.96M | 3.40M | 1.56M | 1.03M | 2.32M | 3.18M | 5.28M |
| Net Income | 588K | -626K | -697K | -208K | 2.12M | 4.02M | -22.4K | -332K | 615K | 1.29M | 4.44M |
| EPS | - | -0.01 | -0.01 | 0.00 | 0.03 | 0.06 | 0.00 | 0.00 | 0.01 | 0.02 | 0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 8.19M | 9.67M | 18.0M | 21.2M | 25.2M | 29.4M | 25.7M | 30.2M | 30.5M | 36.6M | 46.0M |
| Total Liabilities | 7.43M | 7.71M | 16.1M | 19.4M | 19.7M | 19.7M | 16.9M | 22.5M | 22.8M | 29.0M | 36.6M |
| Shareholders' Equity | 758K | 1.96M | 1.96M | 1.84M | 5.52M | 9.71M | 8.85M | 7.71M | 7.62M | 7.62M | 9.39M |
| Cash & Short-term Investments | 681K | 2.03M | 834K | 527K | 802K | 2.32M | 1.77M | 1.88M | 1.71M | 4.78M | 3.57M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 491K | -257K | -507K | 1.05M | 2.65M | 3.82M | 1.07M | 1.28M | 1.15M | 4.98M | -659K |
| Capital Expenditure | 355K | 38.2K | 34.4K | 50.8K | 121K | 127K | 389K | 248K | 318K | 345K | 554K |
| Free Cash Flow | - | -722K | -911K | 88.9K | 1.58M | 2.45M | 559K | 1.03M | 833K | 4.63M | -1.21M |
| Ratios | |||||||||||
| ROE | 77.5% | -31.9% | -35.6% | -11.3% | 38.3% | 41.4% | -0.3% | -4.3% | 8.1% | 16.9% | 47.3% |
| ROA | 7.2% | -6.5% | -3.9% | -1.0% | 8.4% | 13.6% | -0.1% | -1.1% | 2.0% | 3.5% | 9.7% |
| Net Profit Margin | 10.2% | -11.0% | -9.7% | -2.2% | 19.2% | 33.9% | -0.2% | -2.4% | 3.7% | 7.2% | 21.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NexgenRX Inc. dividends
- Dividend yield
- 2.76%
- Forward dividend
- 0.02 CAD
- Payout ratio
- 100.6%
- Ex-dividend date
- Nov 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CAD 1.30M | 0.02 | 100.6% |
| 2024 | CAD 908K | 0.01 | 147.8% |
| 2023 | CAD 902K | 0.01 | - |
| 2022 | CAD 901K | 0.01 | - |
| 2021 | CAD 130K | 0.00 | 3.2% |
| 2020 | CAD 130K | 0.00 | 6.2% |
| 2019 | CAD 130K | 0.00 | - |
| 2018 | CAD 130K | 0.00 | - |
| 2017 | CAD 64.5K | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns NexgenRX Inc.
- Insiders 36.99%
- Institutions 0.00%
- Public & others 63.02%
- Shares outstanding 71.1M
- Free float 44.8M
NexgenRX Inc. company profile
- Company name
- NexgenRX Inc.
- Ticker
- NXG.V
- ISIN
- CA65337X1042
- Exchange
- TSX Venture Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- December
- Address
- 191 The West Mall, Toronto, ON, Canada, M9C 5K8
- Phone
- 416 695 3393
- Website
- nexgenrx.com
About NexgenRX Inc.
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. The company offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. It also provides proprietary computer software, and ancillary services. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada.
NexgenRX Inc. management
8- Mr. Ronald C. Loucks B.B.A.Founder, CEO, President & Director · born 1950
- Mr. Kelly Ehler C.A., CPAChief Financial Officer
- Mr. Andrew MunroeVice President of Operations
- Mr. B. J. PaddaDirector of Implementation
- Mr. Richard StevensVice President of Administration
- Ms. Doreen HarveyLead Human Resources
- Mr. Paul Anthony Bolger LL.B., M.B.A.Company Secretary
- Mr. Avik DebroyFinancial Controller